

Jagpreet Chhatwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1792682/publications.pdf>

Version: 2024-02-01

106
papers

3,833
citations

126858

33
h-index

143943

57
g-index

114
all docs

114
docs citations

114
times ranked

5657
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 280-282.	2.4	4
2	Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: A modeling study. <i>Hepatology</i> , 2022, 75, 1480-1490.	3.6	69
3	Multi-target blood test to improve the performance of hepatocellular carcinoma surveillance programs: A modeling-based virtual trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 405-405.	0.8	1
4	Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100143.	1.5	25
5	Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. <i>Journal of Hepatology</i> , 2022, 77, 55-62.	1.8	19
6	Cost-Effectiveness of a Core Antigen-Based Rapid Diagnostic Test for Hepatitis C. <i>Value in Health</i> , 2022, , .	0.1	1
7	Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?. <i>Value in Health</i> , 2022, , .	0.1	3
8	COVID-19 Health Economics: Looking Back and Scoping the Future. <i>Value in Health</i> , 2022, 25, 695-696.	0.1	3
9	Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions. <i>JAMA Health Forum</i> , 2022, 3, e220760.	1.0	16
10	Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5532-5532.	0.8	0
11	Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5523-5523.	0.8	0
12	Productivity losses under various second-line recurrent or metastatic cervical cancer treatment scenarios in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17520-e17520.	0.8	1
13	A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose. <i>Journal of Substance Abuse Treatment</i> , 2021, 120, 108158.	1.5	76
14	Trends in Thyroid Surgery and Guideline-Concordant Care in the United States, 2007-2018. <i>Thyroid</i> , 2021, 31, 941-949.	2.4	28
15	Incidence Trends and Burden of Human Papillomavirus-Associated Cancers Among Women in the United States, 2001-2017. <i>Journal of the National Cancer Institute</i> , 2021, 113, 792-796.	3.0	35
16	A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China. <i>Clinical Liver Disease</i> , 2021, 17, 99-106.	1.0	4
17	Health Economics of Interventions to Tackle the Coronavirus 2019 Pandemic. <i>Value in Health</i> , 2021, 24, 605-606.	0.1	1
18	Association of Limited In-Person Attendance in US National Football League and National Collegiate Athletic Association Games With County-Level COVID-19 Cases. <i>JAMA Network Open</i> , 2021, 4, e2119621.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Comparative Effectiveness of Implantable Defibrillators for Asymptomatic Brugada Syndrome: A Decision-Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e021144.	1.6	4
20	Comparative Clinical Effectiveness of Population-Based Atrial Fibrillation Screening Using Contemporary Modalities: A Decision-Analytic Model. <i>Journal of the American Heart Association</i> , 2021, 10, e020330.	1.6	4
21	Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator. <i>Scientific Reports</i> , 2021, 11, 21382.	1.6	5
22	Feasibility, effectiveness and cost of a decentralized HCV care model among the general population in Delhi, India. <i>Liver International</i> , 2021, , .	1.9	4
23	Assessing the impact of simplified HCV care on linkage to care amongst high-risk patients at primary healthcare clinics in Malaysia: a prospective observational study. <i>BMJ Open</i> , 2021, 11, e055142.	0.8	6
24	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
25	Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income. <i>Value in Health</i> , 2020, 23, 1552-1560.	0.1	16
26	Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019-40: a modelling study. <i>Lancet Public Health</i> , The, 2020, 5, e316-e323.	4.7	87
27	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108336.	1.6	8
28	Patient and Provider Risk in Managing ST-Elevation Myocardial Infarction During the COVID-19 Pandemic. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e010027.	1.4	4
29	Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. <i>Scientific Reports</i> , 2020, 10, 4089.	1.6	9
30	We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. <i>Pharmacoeconomics</i> , 2020, 38, 427-429.	1.7	1
31	Diagnostic Accuracy of Shear Wave Elastography as a Non-invasive Biomarker of High-Risk Non-alcoholic Steatohepatitis in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2020, 46, 972-980.	0.7	10
32	Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. <i>JAMA Network Open</i> , 2020, 3, e2021173.	2.8	15
33	Reduction of COVID-19 Incidence and Nonpharmacologic Interventions: Analysis Using a US County-Level Policy Data Set. <i>Journal of Medical Internet Research</i> , 2020, 22, e24614.	2.1	25
34	Model to Calculate Harms and Benefits of Early vs Delayed Liver Transplantation for Patients With Alcohol-Associated Hepatitis. <i>Gastroenterology</i> , 2019, 157, 472-480.e5.	0.6	39
35	Alternative Conversion Methods for Transition Probabilities in State-Transition Models: Validity and Impact on Comparative Effectiveness and Cost-Effectiveness. <i>Medical Decision Making</i> , 2019, 39, 509-522.	1.2	2
36	Why should we apply ABM for decision analysis for infectious diseases? An example for dengue interventions. <i>PLoS ONE</i> , 2019, 14, e0221564.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States. JAMA Network Open, 2019, 2, e187621.	2.8	220
38	The impact of direct-acting antivirals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary Pharmacology and Therapeutics, 2019, 50, 66-74.	1.9	37
39	Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. BMJ Open, 2019, 9, e026726.	0.8	34
40	Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. JAMA Network Open, 2019, 2, e193613.	2.8	32
41	Prioritizing Hepatitis C Treatment in U.S. Prisons. Operations Research, 2019, 67, 853-873.	1.2	21
42	Budget Impact Analysis of Cancer Screening: A Methodological Review. Applied Health Economics and Health Policy, 2019, 17, 493-511.	1.0	6
43	Letter to the Editor: Hepatitis C Virus Prevalence Estimates Among Incarcerated Persons. Hepatology, 2019, 70, 758-759.	3.6	4
44	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Network Open, 2019, 2, e190047.	2.8	42
45	Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study. Scientific Reports, 2019, 9, 16849.	1.6	17
46	Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women. JAMA Network Open, 2019, 2, e1918571.	2.8	23
47	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2019, 17, 739-747.e8.	2.4	24
48	Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism. Journal of Correctional Health Care, 2019, 25, 15-24.	0.2	10
49	Universal Screening for Hepatitis C: An Important Step in Virus Elimination. Clinical Gastroenterology and Hepatology, 2019, 17, 835-837.	2.4	16
50	Folic Acid-Containing Dietary Supplement Consumption and Risk of Cardiovascular Diseases in Rheumatoid Arthritis Patients: NHANES 1999-2014. Journal of General Internal Medicine, 2019, 34, 15-16.	1.3	4
51	Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. Molecular and Translational Medicine, 2019, , 53-67.	0.4	5
52	Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe. Journal of Viral Hepatitis, 2018, 25, 6-17.	1.0	65
53	Reply. Hepatology, 2018, 68, 793-793.	3.6	0
54	Hepatitis C virus treatment in the era of direct-acting antivirals: projections in the USA. Alimentary Pharmacology and Therapeutics, 2018, 47, 1023-1031.	1.9	25

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness and Decision Analysis in Clinical Gastroenterology and Hepatology: From Evidence to Informed Decision Making. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 459-461.	2.4	3
56	Reply. <i>Hepatology</i> , 2018, 67, 1641-1642.	3.6	1
57	Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 115-122.e10.	2.4	21
58	Should we treat acute hepatitis C? A decision and cost-effectiveness analysis. <i>Hepatology</i> , 2018, 67, 837-846.	3.6	61
59	Hepatitis C Screening: From Modeling to Public Health Policy. <i>Clinical Infectious Diseases</i> , 2018, 66, 385-386.	2.9	11
60	Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study. <i>Hepatology</i> , 2018, 67, 2085-2095.	3.6	50
61	Reply to L. Yaghjyan et al.. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky046.	1.4	0
62	Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 819.	3.7	23
63	Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers. <i>JAMA Network Open</i> , 2018, 1, e181999.	2.8	54
64	Five Questions Concerning Managing Hepatitis C in the Justice System. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 323-345.	1.9	19
65	Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 461-480.	1.9	15
66	The Association Between Dietary Quality and Overall and Cancer-Specific Mortality Among Cancer Survivors, NHANES III. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky022.	1.4	18
67	Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir <i>versus</i> genotype-dependent direct-acting antivirals for hepatitis C treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 2029-2036.	1.4	31
68	Optimal <i>M</i>-Switch Surveillance Policies for Liver Cancer in a Hepatitis C-Infected Population. <i>Operations Research</i> , 2018, 66, 673-696.	1.2	18
69	Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-174.	0.8	131
70	Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. <i>Healthcare</i> , 2017, 5, 105-111.	0.6	5
71	Acceptance of Surgical Treatment for Adolescent Obesity-Reply. <i>JAMA Surgery</i> , 2017, 152, 802.	2.2	0
72	From Data to Improved Decisions: Operations Research in Healthcare Delivery. <i>Medical Decision Making</i> , 2017, 37, 849-859.	1.2	25

#	ARTICLE	IF	CITATIONS
73	Reply. Hepatology, 2017, 66, 1005-1006.	3.6	0
74	Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness. Cancer, 2017, 123, 4709-4719.	2.0	29
75	Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 2014. Annals of Internal Medicine, 2017, 167, 714.	2.0	112
76	Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2€6. Alimentary Pharmacology and Therapeutics, 2017, 46, 711-721.	1.9	52
77	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1981.	2.4	0
78	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1815.	2.4	0
79	Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. Vaccine, 2017, 35, 5102-5109.	1.7	20
80	Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology, 2017, 65, 920-928.	3.6	70
81	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. JAMA Surgery, 2017, 152, 136.	2.2	62
82	Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdominal Radiology, 2017, 42, 179-190.	1.0	113
83	Sensitivity Analysis in Sequential Decision Models. Medical Decision Making, 2017, 37, 243-252.	1.2	13
84	Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clinical Gastroenterology and Hepatology, 2017, 15, 827-837.e8.	2.4	81
85	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology, 2017, 65, 777-788.	3.6	83
86	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology, 2017, 65, 1156-1164.	3.6	76
87	Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India. PLoS ONE, 2017, 12, e0176503.	1.1	79
88	Reply to C. Nabhan et al. Journal of Clinical Oncology, 2017, 35, 1864-1865.	0.8	1
89	Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Annals of Internal Medicine, 2016, 164, 84.	2.0	137
90	Myths and Misconceptions of Within-Cycle Correction: A Guide for Modelers and Decision Makers. Pharmacoeconomics, 2016, 34, 13-22.	1.7	18

#	ARTICLE	IF	CITATIONS
91	Changing Cycle Lengths in State-Transition Models. <i>Medical Decision Making</i> , 2016, 36, 952-964.	1.2	38
92	Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. <i>Hepatology</i> , 2016, 64, 1442-1450.	3.6	126
93	Theoretical Foundations and Practical Applications of Within-Cycle Correction Methods. <i>Medical Decision Making</i> , 2016, 36, 115-131.	1.2	23
94	Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. <i>Pharmacoeconomics</i> , 2016, 34, 551-567.	1.7	74
95	Clinical Impact of Alcohol-Related Cirrhosis in the Next Decade: Estimates Based on Current Epidemiological Trends in the United States. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 2085-2094.	1.4	70
96	Are high drug prices for hematologic malignancies justified? A critical analysis. <i>Cancer</i> , 2015, 121, 3372-3379.	2.0	43
97	Economic Evaluations with Agent-Based Modelling: An Introduction. <i>Pharmacoeconomics</i> , 2015, 33, 423-433.	1.7	38
98	Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2015, 61, 1527-1535.	2.9	41
99	Why We Should Be Willing to Pay for Hepatitis C Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1711-1713.	2.4	10
100	Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. <i>Annals of Internal Medicine</i> , 2015, 162, 397-406.	2.0	303
101	The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions. <i>Annals of Internal Medicine</i> , 2014, 161, 170.	2.0	129
102	Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. <i>BMC Infectious Diseases</i> , 2013, 13, 190.	1.3	48
103	Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 65-78.	1.0	34
104	Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States. <i>Value in Health</i> , 2013, 16, 973-986.	0.1	63
105	Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. <i>Journal of Health Economics and Outcomes Research</i> , 2013, 1, 62-82.	0.6	2
106	Optimal Breast Biopsy Decision-Making Based on Mammographic Features and Demographic Factors. <i>Operations Research</i> , 2010, 58, 1577-1591.	1.2	94